Literature DB >> 15461917

Urologic applications of botulinum toxin therapy for voiding dysfunction.

Raymond Rackley1, Joseph Abdelmalak.   

Abstract

Botulinum toxin is primarily a presynaptic neuromuscular blocking agent inducing selective and reversible muscle weakness up to several months when injected intramuscularly in small quantities. The clinical use of botulinum toxin type-A has gained widespread acceptance and application for numerous adult and pediatric spasticity syndromes. This has led to the urologic adoption of this minimally invasive therapy for the treatment of idiopathic and neurogenic detrusor overactivity, interstitial cystitis, detrusor-sphincter dyssynergia, urinary retention, and prostatic conditions. Outlined below is an overview of the clinical adoption of this therapy for the treatment of various dysfunctions of the lower urinary tract.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15461917     DOI: 10.1007/s11934-004-0088-5

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  25 in total

Review 1.  Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions.

Authors:  K R Aoki; B Guyer
Journal:  Eur J Neurol       Date:  2001-11       Impact factor: 6.089

2.  Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia.

Authors:  J Jankovic; K D Vuong; J Ahsan
Journal:  Neurology       Date:  2003-04-08       Impact factor: 9.910

3.  Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients.

Authors:  D D Dykstra; A A Sidi; A B Scott; J M Pagel; G D Goldish
Journal:  J Urol       Date:  1988-05       Impact factor: 7.450

Review 4.  Bacterial toxins: a table of lethal amounts.

Authors:  D M Gill
Journal:  Microbiol Rev       Date:  1982-03

5.  Botox-induced prostatic involution.

Authors:  R Doggweiler; D H Zermann; M Ishigooka; R A Schmidt
Journal:  Prostate       Date:  1998-09-15       Impact factor: 4.104

6.  Botulinum A toxin effects on rat jaw muscle spindles.

Authors:  G M Filippi; P Errico; R Santarelli; B Bagolini; E Manni
Journal:  Acta Otolaryngol       Date:  1993-05       Impact factor: 1.494

7.  Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study.

Authors:  Giorgio Maria; Giuseppe Brisinda; Ignazio Massimo Civello; Anna Rita Bentivoglio; Gabriele Sganga; Alberto Albanese
Journal:  Urology       Date:  2003-08       Impact factor: 2.649

Review 8.  Botulinum toxin as a new therapy option for voiding disorders: current state of the art.

Authors:  Thomas Leippold; André Reitz; Brigitte Schurch
Journal:  Eur Urol       Date:  2003-08       Impact factor: 20.096

Review 9.  Emerging role of botulinum toxin in the management of voiding dysfunction.

Authors:  Christopher P Smith; Michael B Chancellor
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

10.  Physiological effects produced by botulinum toxin treatment of upper limb dystonia. Changes in reciprocal inhibition between forearm muscles.

Authors:  A Priori; A Berardelli; B Mercuri; M Manfredi
Journal:  Brain       Date:  1995-06       Impact factor: 13.501

View more
  3 in total

Review 1.  [Botulinum toxin for the treatment of neurogenic detrusor hyperactivity. Consensus paper on use for neurogenic bladder dysfunction].

Authors:  K-D Sievert; J Bremer; H Burgdörfer; B Domurath; C Hampel; J Kutzenberger; C Seif; M Stöhrer; B Wefer; J Pannek
Journal:  Urologe A       Date:  2007-03       Impact factor: 0.639

2.  [Seven years of botulinum toxin type A in the treatment of neurogenic detrusor hyperactivity].

Authors:  M Stöhrer; A Wolff; G Kramer; R Steiner; D Löchner-Ernst; D Leuth; U Steude; H Rübben
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

3.  Botulinum a toxin/dimethyl sulfoxide bladder instillations for women with refractory idiopathic detrusor overactivity: a phase 1/2 study.

Authors:  Steven P Petrou; Alexander S Parker; Julia E Crook; Alexandra Rogers; Dorothea Metz-Kudashick; David D Thiel
Journal:  Mayo Clin Proc       Date:  2009-08       Impact factor: 7.616

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.